{"pmid":32395179,"pmcid":"PMC7206578","title":"Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report.","text":["Successful COVID-19 rescue therapy by extra-corporeal membrane oxygenation (ECMO) for respiratory failure: a case report.","Background: The value of extracorporeal membrane oxygenation (ECMO) for patients suffering from novel coronavirus disease 2019 (COVID-19) as a rescue therapy for respiratory failure remains controversial and associated with high mortality rates of 50 to 82% in early reports from Wuhan, China. We hypothesized that patient outcomes would be improved at our tertiary cardiothoracic surgery referral center with a protocolized team-approach for ECMO treatment of patients with severe COVID-19 disease. Case presentation: A 51-year-old healthy female developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bilateral pneumonia while vacationing in Colorado with her family. She was transferred to our facility for a higher level of care. Her respiratory status continued to deteriorate despite maximized critical care, including prone positioning ventilation and nitric oxide inhalation therapy. Veno-venous ECMO was initiated on hospital day 7 in conjunction with a 10-day course of compassionate use antiviral treatment with remdesivir. The patient's condition improved significantly and she was decannulated from ECMO on hospital day 17 (ECMO day 11). She was successfully extubated and eventually discharged to rehabilitation on hospital day 28. Conclusion: This case report demonstrates a positive outcome in a young patient with COVID-19 treated by the judicious application of ECMO in conjunction with compassionate use antiviral treatment (remdesivir). Future prospective multi-center studies are needed to validate these findings in a larger cohort of patients.","Patient Saf Surg","Firstenberg, Michael S","Stahel, Philip F","Hanna, Jennifer","Kotaru, Chakradhar","Crossno, Joseph Jr","Forrester, Joseph","32395179"],"abstract":["Background: The value of extracorporeal membrane oxygenation (ECMO) for patients suffering from novel coronavirus disease 2019 (COVID-19) as a rescue therapy for respiratory failure remains controversial and associated with high mortality rates of 50 to 82% in early reports from Wuhan, China. We hypothesized that patient outcomes would be improved at our tertiary cardiothoracic surgery referral center with a protocolized team-approach for ECMO treatment of patients with severe COVID-19 disease. Case presentation: A 51-year-old healthy female developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) bilateral pneumonia while vacationing in Colorado with her family. She was transferred to our facility for a higher level of care. Her respiratory status continued to deteriorate despite maximized critical care, including prone positioning ventilation and nitric oxide inhalation therapy. Veno-venous ECMO was initiated on hospital day 7 in conjunction with a 10-day course of compassionate use antiviral treatment with remdesivir. The patient's condition improved significantly and she was decannulated from ECMO on hospital day 17 (ECMO day 11). She was successfully extubated and eventually discharged to rehabilitation on hospital day 28. Conclusion: This case report demonstrates a positive outcome in a young patient with COVID-19 treated by the judicious application of ECMO in conjunction with compassionate use antiviral treatment (remdesivir). Future prospective multi-center studies are needed to validate these findings in a larger cohort of patients."],"journal":"Patient Saf Surg","authors":["Firstenberg, Michael S","Stahel, Philip F","Hanna, Jennifer","Kotaru, Chakradhar","Crossno, Joseph Jr","Forrester, Joseph"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395179","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1186/s13037-020-00245-7","keywords":["covid-19","coronavirus","extra-corporeal membrane oxygenation","lung injury","remdesivir treatment","sars-cov-2"],"locations":["Wuhan","China","cardiothoracic","Colorado"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"e_drugs":["Nitric Oxide","remdesivir"],"topics":["Case Report"],"weight":1,"_version_":1666627827875708929,"score":9.490897,"similar":[{"pmid":32313662,"pmcid":"PMC7161844","title":"Veno-venous extracorporeal membrane oxygenation for severe pneumonia: COVID-19 case in Japan.","text":["Veno-venous extracorporeal membrane oxygenation for severe pneumonia: COVID-19 case in Japan.","Background: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is one of the ultimate treatments for acute respiratory failure. However, the effectiveness of ECMO in patients with novel coronavirus disease (COVID-19) is unknown. Case Presentation: A 72-year-old woman who was a passenger of a cruise ship tested positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while in quarantine on board using throat swab. Three days after admission, her condition deteriorated, and she was subsequently intubated. On day 6, VV-ECMO was introduced. Lopinavir/ritonavir was given; continuous renal replacement therapy was also introduced. On day 10, her chest radiography and lung compliance improved. She was weaned off ECMO on day 12. Conclusion: Treatment of severe pneumonia in COVID-19 by ECMO should recognize lung plasticity considering time to ECMO introduction and interstitial biomarkers. In Japan, centralization of ECMO patients has not been sufficient. Thus, we suggest nationwide centralization and further research to respond to the crisis caused by COVID-19.","Acute Med Surg","Taniguchi, Hayato","Ogawa, Fumihiro","Honzawa, Hiroshi","Yamaguchi, Keishi","Niida, Shoko","Shinohara, Mafumi","Takahashi, Kohei","Iwashita, Masayuki","Abe, Takeru","Kubo, Sousuke","Kudo, Makoto","Takeuchi, Ichiro","32313662"],"abstract":["Background: Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is one of the ultimate treatments for acute respiratory failure. However, the effectiveness of ECMO in patients with novel coronavirus disease (COVID-19) is unknown. Case Presentation: A 72-year-old woman who was a passenger of a cruise ship tested positive for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while in quarantine on board using throat swab. Three days after admission, her condition deteriorated, and she was subsequently intubated. On day 6, VV-ECMO was introduced. Lopinavir/ritonavir was given; continuous renal replacement therapy was also introduced. On day 10, her chest radiography and lung compliance improved. She was weaned off ECMO on day 12. Conclusion: Treatment of severe pneumonia in COVID-19 by ECMO should recognize lung plasticity considering time to ECMO introduction and interstitial biomarkers. In Japan, centralization of ECMO patients has not been sufficient. Thus, we suggest nationwide centralization and further research to respond to the crisis caused by COVID-19."],"journal":"Acute Med Surg","authors":["Taniguchi, Hayato","Ogawa, Fumihiro","Honzawa, Hiroshi","Yamaguchi, Keishi","Niida, Shoko","Shinohara, Mafumi","Takahashi, Kohei","Iwashita, Masayuki","Abe, Takeru","Kubo, Sousuke","Kudo, Makoto","Takeuchi, Ichiro"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313662","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/ams2.509","keywords":["coronavirus disease 2019","japan","extracorporeal membrane oxygenation","lopinavir","ritonavir","severe acute respiratory syndrome coronavirus 2"],"locations":["Veno","Japan","Japan"],"countries":["Japan"],"countries_codes":["JPN|Japan"],"e_drugs":["lopinavir-ritonavir drug combination"],"topics":["Case Report"],"weight":1,"_version_":1666138493461463040,"score":266.58823},{"pmid":32431992,"pmcid":"PMC7233513","title":"Extracorporeal Membrane Oxygenation as Treatment of Severe COVID-19 Infection: A Case Report.","text":["Extracorporeal Membrane Oxygenation as Treatment of Severe COVID-19 Infection: A Case Report.","Novel coronavirus 2019 (COVID-19) is a severe respiratory infection leading to acute respiratory distress syndrome (ARDS) accounting for thousands of cases and deaths across the world. Several alternatives in treatment options have been assessed and used in this patient population. However, when mechanical ventilation and prone positioning are unsuccessful, venovenous extracorporeal membrane oxygenation (VV-ECMO) may be used. We present a case of a 41-year-old female, with no significant medical history and no recent history of exposure to sick contacts, presented to the emergency department (ED) with fever, severe shortness of breath, and flu-like symptoms with a positive COVID-19 test. Ultimately, she worsened on mechanical ventilation and prone positioning and required VV-ECMO. The use of VV-ECMO in COVID-19 infected patients is still controversial. While some studies have shown a high mortality rate despite aggressive treatment, such as in our case, the lack of large sample size studies and treatment alternatives places healthcare providers against a wall without options in patients with severe refractory ARDS due to COVID-19.","Cureus","Douedi, Steven","Alshami, Abbas","Costanzo, Eric","32431992"],"abstract":["Novel coronavirus 2019 (COVID-19) is a severe respiratory infection leading to acute respiratory distress syndrome (ARDS) accounting for thousands of cases and deaths across the world. Several alternatives in treatment options have been assessed and used in this patient population. However, when mechanical ventilation and prone positioning are unsuccessful, venovenous extracorporeal membrane oxygenation (VV-ECMO) may be used. We present a case of a 41-year-old female, with no significant medical history and no recent history of exposure to sick contacts, presented to the emergency department (ED) with fever, severe shortness of breath, and flu-like symptoms with a positive COVID-19 test. Ultimately, she worsened on mechanical ventilation and prone positioning and required VV-ECMO. The use of VV-ECMO in COVID-19 infected patients is still controversial. While some studies have shown a high mortality rate despite aggressive treatment, such as in our case, the lack of large sample size studies and treatment alternatives places healthcare providers against a wall without options in patients with severe refractory ARDS due to COVID-19."],"journal":"Cureus","authors":["Douedi, Steven","Alshami, Abbas","Costanzo, Eric"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32431992","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.7759/cureus.7714","keywords":["ards","coronavirus","covid-19","ecmo","infection","respiratory"],"topics":["Case Report"],"weight":1,"_version_":1667342288320200704,"score":263.45837},{"pmid":32452947,"title":"Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America.","text":["Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America.","AND BACKGROUND DATA: VV ECMO can be utilized as an advanced therapy in select patients with COVID-19 respiratory failure refractory to traditional critical care management and optimal mechanical ventilation. Anticipating a need for such therapies during the pandemic, our center created a targeted protocol for ECMO therapy in COVID-19 patients that allows us to provide this life-saving therapy to our sickest patients without overburdening already stretched resources or excessively exposing healthcare staff to infection risk. METHODS: As a major regional referral program, we used the framework of our well-established ECMO service-line to outline specific team structures, modified patient eligibility criteria, cannulation strategies, and management protocols for the COVID-19 ECMO program. RESULTS: During the first month of the COVID-19 outbreak in Massachusetts, 6 patients were placed on VV ECMO for refractory hypoxemic respiratory failure. The median (interquartile range) age was 47 years (43-53) with most patients being male (83%) and obese (67%). All cannulations were performed at the bedside in the intensive care unit in patients who had undergone a trial of rescue therapies for acute respiratory distress syndrome including lung protective ventilation, paralysis, prone positioning, and inhaled nitric oxide. At the time of this report, 83% (5/6) of the patients are still alive with 1 death on ECMO, attributed to hemorrhagic stroke. 67% of patients (4/6) have been successfully decannulated, including 2 that have been successfully extubated and one who was discharged from the hospital. The median duration of VV ECMO therapy for patients who have been decannulated is 12 days (4-18 days). CONCLUSIONS: This is 1 the first case series describing VV ECMO outcomes in COVID-19 patients. Our initial data suggest that VV ECMO can be successfully utilized in appropriately selected COVID-19 patients with advanced respiratory failure.","Ann Surg","Osho, Asishana A","Moonsamy, Philicia","Hibbert, Kathryn A","Shelton, Kenneth T","Trahanas, John M","Attia, Rizwan Q","Bloom, Jordan P","Onwugbufor, Michael T","D'Alessandro, David A","Villavicencio, Mauricio A","Sundt, Thoralf M","Crowley, Jerome C","Raz, Yuval","Funamoto, Masaki","32452947"],"abstract":["AND BACKGROUND DATA: VV ECMO can be utilized as an advanced therapy in select patients with COVID-19 respiratory failure refractory to traditional critical care management and optimal mechanical ventilation. Anticipating a need for such therapies during the pandemic, our center created a targeted protocol for ECMO therapy in COVID-19 patients that allows us to provide this life-saving therapy to our sickest patients without overburdening already stretched resources or excessively exposing healthcare staff to infection risk. METHODS: As a major regional referral program, we used the framework of our well-established ECMO service-line to outline specific team structures, modified patient eligibility criteria, cannulation strategies, and management protocols for the COVID-19 ECMO program. RESULTS: During the first month of the COVID-19 outbreak in Massachusetts, 6 patients were placed on VV ECMO for refractory hypoxemic respiratory failure. The median (interquartile range) age was 47 years (43-53) with most patients being male (83%) and obese (67%). All cannulations were performed at the bedside in the intensive care unit in patients who had undergone a trial of rescue therapies for acute respiratory distress syndrome including lung protective ventilation, paralysis, prone positioning, and inhaled nitric oxide. At the time of this report, 83% (5/6) of the patients are still alive with 1 death on ECMO, attributed to hemorrhagic stroke. 67% of patients (4/6) have been successfully decannulated, including 2 that have been successfully extubated and one who was discharged from the hospital. The median duration of VV ECMO therapy for patients who have been decannulated is 12 days (4-18 days). CONCLUSIONS: This is 1 the first case series describing VV ECMO outcomes in COVID-19 patients. Our initial data suggest that VV ECMO can be successfully utilized in appropriately selected COVID-19 patients with advanced respiratory failure."],"journal":"Ann Surg","authors":["Osho, Asishana A","Moonsamy, Philicia","Hibbert, Kathryn A","Shelton, Kenneth T","Trahanas, John M","Attia, Rizwan Q","Bloom, Jordan P","Onwugbufor, Michael T","D'Alessandro, David A","Villavicencio, Mauricio A","Sundt, Thoralf M","Crowley, Jerome C","Raz, Yuval","Funamoto, Masaki"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32452947","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1097/SLA.0000000000004084","locations":["Massachusetts","obese"],"countries":["United States"],"countries_codes":["USA|United States"],"e_drugs":["Nitric Oxide"],"topics":["Treatment"],"weight":1,"_version_":1667881798499041281,"score":257.3452},{"pmid":32304395,"title":"COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support.","text":["COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support.","The outbreak of novel coronavirus (SARS-CoV-2) which causes the respiratory illness COVID-19 has led to unprecedented efforts at containment due to its rapid community spread, associated mortality, and lack of immunization and treatment. We herein detail a case of a young patient who suffered life-threatening disease and multi-organ failure. His clinical course involved rapid and profound respiratory decompensation such that he required support with veno-venous extracorporeal membrane oxygenation (VV-ECMO). He also demonstrated hyperinflammation (C-reactive protein peak 444.6 mg/L) with severe cytokine elevation (Interleukin-6 peak > 3,000 pg/mL). Through treatment targeting hyperinflammation he recovered from critical COVID-19 respiratory failure and required only 160 hours of VV-ECMO support. He is currently extubated without an oxygen requirement, showing signs of renal recovery on intermittent hemodialysis, and his repeat SARS-CoV-2 test is negative 21 days after his first positive test. We present the first successful case of VV-ECMO support to recovery of COVID-19 respiratory failure in North America.","ASAIO J","Hartman, Matthew E","Hernandez, Roland A","Patel, Krish","Wagner, Teresa E","Trinh, Tony","Lipke, Anne B","Yim, Eric T","Pulido, Juan N","Pagel, John M","Youssef, Samuel J","Mignone, John L","32304395"],"abstract":["The outbreak of novel coronavirus (SARS-CoV-2) which causes the respiratory illness COVID-19 has led to unprecedented efforts at containment due to its rapid community spread, associated mortality, and lack of immunization and treatment. We herein detail a case of a young patient who suffered life-threatening disease and multi-organ failure. His clinical course involved rapid and profound respiratory decompensation such that he required support with veno-venous extracorporeal membrane oxygenation (VV-ECMO). He also demonstrated hyperinflammation (C-reactive protein peak 444.6 mg/L) with severe cytokine elevation (Interleukin-6 peak > 3,000 pg/mL). Through treatment targeting hyperinflammation he recovered from critical COVID-19 respiratory failure and required only 160 hours of VV-ECMO support. He is currently extubated without an oxygen requirement, showing signs of renal recovery on intermittent hemodialysis, and his repeat SARS-CoV-2 test is negative 21 days after his first positive test. We present the first successful case of VV-ECMO support to recovery of COVID-19 respiratory failure in North America."],"journal":"ASAIO J","authors":["Hartman, Matthew E","Hernandez, Roland A","Patel, Krish","Wagner, Teresa E","Trinh, Tony","Lipke, Anne B","Yim, Eric T","Pulido, Juan N","Pagel, John M","Youssef, Samuel J","Mignone, John L"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304395","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1097/MAT.0000000000001177","topics":["Case Report"],"weight":1,"_version_":1666138491050786817,"score":240.76834},{"pmid":32243266,"title":"Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.","text":["Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019 in Shanghai, China.","Severe cases of coronavirus disease 2019 (COVID-19) cannot be adequately managed with mechanical ventilation alone. The role and outcome of extracorporeal membrane oxygenation (ECMO) in the management of COVID-19 is currently unclear. Eight COVID-19 patients have received ECMO support in Shanghai with seven with venovenous (VV) ECMO support and one veno arterial (VA) ECMO during cardiopulmonary resuscitation. As of March 25, 2020, four patients died (50% mortality), three patients (37.5%) were successfully weaned off ECMO after 22, 40, and 47 days support, respectively, but remain on mechanical ventilation. One patient is still on VV ECMO with mechanical ventilation. The partial pressure of oxygen/fractional of inspired oxygen ratio before ECMO initiation was between 54 and 76, and all were well below 100. The duration of mechanical ventilation before ECMO ranged from 4 to 21 days. Except the one emergent VA ECMO during cardiopulmonary resuscitation, other patients were on ECMO support for between 18 and 47 days. In conclusion, ensuring effective, timely, and safe ECMO support in COVID-19 is key to improving clinical outcomes. Extracorporeal membrane oxygenation support might be an integral part of the critical care provided for COVID-19 patients in centers with advanced ECMO expertise.","ASAIO J","Li, Xin","Guo, Zhen","Li, Bailing","Zhang, Xiaolin","Tian, Rui","Wu, Wei","Zhang, Zhongwei","Lu, Yunfei","Chen, Nan","Clifford, Sean P","Huang, Jiapeng","32243266"],"abstract":["Severe cases of coronavirus disease 2019 (COVID-19) cannot be adequately managed with mechanical ventilation alone. The role and outcome of extracorporeal membrane oxygenation (ECMO) in the management of COVID-19 is currently unclear. Eight COVID-19 patients have received ECMO support in Shanghai with seven with venovenous (VV) ECMO support and one veno arterial (VA) ECMO during cardiopulmonary resuscitation. As of March 25, 2020, four patients died (50% mortality), three patients (37.5%) were successfully weaned off ECMO after 22, 40, and 47 days support, respectively, but remain on mechanical ventilation. One patient is still on VV ECMO with mechanical ventilation. The partial pressure of oxygen/fractional of inspired oxygen ratio before ECMO initiation was between 54 and 76, and all were well below 100. The duration of mechanical ventilation before ECMO ranged from 4 to 21 days. Except the one emergent VA ECMO during cardiopulmonary resuscitation, other patients were on ECMO support for between 18 and 47 days. In conclusion, ensuring effective, timely, and safe ECMO support in COVID-19 is key to improving clinical outcomes. Extracorporeal membrane oxygenation support might be an integral part of the critical care provided for COVID-19 patients in centers with advanced ECMO expertise."],"journal":"ASAIO J","authors":["Li, Xin","Guo, Zhen","Li, Bailing","Zhang, Xiaolin","Tian, Rui","Wu, Wei","Zhang, Zhongwei","Lu, Yunfei","Chen, Nan","Clifford, Sean P","Huang, Jiapeng"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243266","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1097/MAT.0000000000001172","link_comment_in":"32341268","locations":["Shanghai","Shanghai","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138492129771523,"score":234.61314}]}